Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy

被引:2
|
作者
Atik, Alp [1 ,2 ]
Hu, Yijun [3 ]
Yu, Honghua [4 ]
Yang, Chun [5 ]
Cai, Bin [1 ]
Tao, Yijing [1 ]
Li, Dongli [1 ]
Chen, Yan [1 ]
Lu, Li [1 ]
Li, Guodong [6 ]
Yuan, Ling [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 295 Xichang Rd, Kunming 650031, Yunnan, Peoples R China
[2] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia
[3] Shanwei Project Vis Eye Hosp, Shanwei, Peoples R China
[4] Gen Hosp Guangzhou Mil Command PLA, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China
[5] Peoples Hosp Gejiu City, Dept Ophthalmol, Gejiu, Peoples R China
[6] Nanchang Univ, Affiliated Hosp 2, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China
来源
BMC OPHTHALMOLOGY | 2017年 / 17卷
基金
中国国家自然科学基金;
关键词
Central serous chorioretinopathy (CSCR); Photodynamic therapy (PDT); Visual field; Macular sensitivity; Automated static perimetry; VISUAL FUNCTION; RETINAL SENSITIVITY; FUNDUS PERIMETRY; VERTEPORFIN; ACUITY; RANIBIZUMAB; THRESHOLD; FLUENCE; VISION; UPDATE;
D O I
10.1186/s12886-017-0535-y
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: To evaluate the macular sensitivity changes after half-dose photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSCR). Methods: Eighteen patients (26 eyes) with chronic CSCR were recruited in the same hospital between April 2011 and December 2012. All patients were treated with one session of half-dose PDT after complete ophthalmic examination. Macular sensitivity examination was performed at baseline and 1, 3 and 6 months post-treatment. Mean sensitivity (MS) of the central 10 degrees (10 degrees) and 4 degrees (4 degrees), mean deviation (MD) and pattern standard deviation (PSD) on automated static perimetry (Humphrey Field Analyzer II-750) were used for analysis. Results: There was significant improvement of the 10 degrees MS from baseline (29.76 +/- 1.51 dB) to 1 month (31.74 +/- 1.56 dB), 3 months (31.51 +/- 1.38 dB) and 6 months (31.19 +/- 1.61 dB) after treatment (P < 0.001). The 4 degrees MS was also significantly improved with half-dose PDT from baseline (28.96 +/- 1.78 dB) to 1 month (32.41 +/- 1.66 dB), 3 months (32.46 +/- 1.50 dB) and 6 months (31.90 +/- 1.84 dB) post-treatment (P < 0.001). MD was improved from baseline (-3.39 +/- 0.89 dB) to 1 month (-1.96 +/- 0.29 dB), 3 months (-1.94 +/- 0.29 dB) and 6 months (-2.45 +/- 0.13) post-treatment (P = 0.004). PSD also improved from 1.97 +/- 0.24 dB at baseline to 1.47 +/- 0.27 dB, 1.34 +/- 0.24 dB, and 1.53 +/- 0.24 dB (P = 0.001) at 1, 3 and 6 months after treatment, respectively. Conclusion: Macular sensitivity in CSCR can be improved by half-dose PDT, along with improvement of visual acuity and retinal thickness. The treatment outcome at 1 month may be a predictor of the final treatment response.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Short-Term Choriocapillaris Changes in Patients with Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
    Nassisi, Marco
    Lavia, Carlo
    Alovisi, Camilla
    Musso, Luca
    Eandi, Chiara M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (11):
  • [32] Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking
    Etsuyo Horiguchi
    Jun Takeuchi
    Ryo Tomita
    Keiko Asai
    Yuyako Nakano
    Hikaru Ota
    Yosuke Taki
    Yasuki Ito
    Hiroko Terasaki
    Koji M. Nishiguchi
    Keiko Kataoka
    Scientific Reports, 12
  • [33] Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy
    Ratanasukon, Mansing
    Thongthong, Koblarp
    Bhurayanontachai, Patama
    Jirarattanasopa, Pichai
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 87 - 92
  • [34] Half-Dose Verteporfin Photodynamic Therapy (hdPDT) in the Treatment of Central Serous Chorioretinopathy
    Hoehn, F.
    Kretz, F. T. A.
    Beger, I.
    Koch, F.
    Auffarth, G. U.
    Singh, P.
    Deuchler, S.
    Koss, M. J.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2016, 233 (07) : 860 - 863
  • [35] Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking
    Horiguchi, Etsuyo
    Takeuchi, Jun
    Tomita, Ryo
    Asai, Keiko
    Nakano, Yuyako
    Ota, Hikaru
    Taki, Yosuke
    Ito, Yasuki
    Terasaki, Hiroko
    Nishiguchi, Koji M.
    Kataoka, Keiko
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [36] Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy
    Izumi, Takahiko
    Koizumi, Hideki
    Maruko, Ichiro
    Takahashi, Yohei
    Sonoda, Shozo
    Sakamoto, Taiji
    Iida, Tomohiro
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (04) : 433 - 437
  • [37] Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy
    Yu-Te Huang
    Peng-Tai Tien
    Po-Yu Chen
    Chi-Lan Yang
    San-Ni Chen
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262 : 1755 - 1763
  • [38] Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy A case report
    Zhang, Zhengwei
    Bao, Xiaona
    Wu, Zhifeng
    Zhang, Jie
    MEDICINE, 2021, 100 (07) : E24790
  • [39] Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy
    Huang, Yu-Te
    Tien, Peng-Tai
    Chen, Po-Yu
    Yang, Chi-Lan
    Chen, San-Ni
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (06) : 1755 - 1763
  • [40] One-Year Outcomes with Half-Dose Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
    Fujita, Kyoko
    Imamura, Yutaka
    Shinoda, Kei
    Matsumoto, Celso Soiti
    Mizutani, Yoshihiro
    Hashizume, Kouhei
    Mizota, Atsushi
    Yuzawa, Mitsuko
    OPHTHALMOLOGY, 2015, 122 (03) : 555 - 561